Skip to content
MarketScale
‹ Back to IndustriesHealthcare

New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s Disease

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimer’s in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimer’s disease medications are giving new options to patients.

“Alzheimer’s research is getting to a place where cancer research was maybe 30, 40 years ago,” says Anton Porsteinsson, MD, director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. “I think we’re at a point where we’re going to see a logarithmic increase in discovery.”

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dung’s Thoughts

“Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimer’s disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinson’s disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best we’ve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently. ”

Article written by Sonya Young.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Digital health's July 2026 signal: AI wearables, a new CMS office, and the telehealth billing fight

Digital health's July 2026 signal: AI wearables, a new CMS office, and the telehealth billing fight

In mid-2026, digital health is evolving with significant advancements such as AI-driven wearables and innovations in healthcare billing processes involving telehealth. A notable cardiac patch boasting 99.6% accuracy highlights progress in wearable technology. Meanwhile, the establishment of a new CMS AI office demonstrates the growing institutional interest in integrating AI into healthcare operations.

  • 01AI wearables are being developed with high accuracy in health monitoring.
  • 02The establishment of a CMS AI office indicates increased government focus on AI in healthcare.
  • 03Debates over telehealth billing practices continue to shape the healthcare landscape.

Jul 5, 2026

OpenLoop acquires AI communication platform Hey Revia as digital health M&A heats up

OpenLoop acquires AI communication platform Hey Revia as digital health M&A heats up

OpenLoop has acquired AI communication platform Hey Revia as part of growing M&A activity in the digital health sector. The acquisition reflects an ongoing trend in digital health mergers and partnerships, including the announcement of FDA breakthrough status for Aurenar and Sharecare's collaboration with AWS. These developments highlight the increasing investment and strategic alliances shaping the digital health landscape.

  • 01OpenLoop acquires AI communication platform Hey Revia.
  • 02FDA grants Aurenar breakthrough status.
  • 03Sharecare partners with AWS to enhance digital health solutions.

Jul 4, 2026

Healthcare AI governance, data quality, and interoperability top industry agenda in mid-2026

Healthcare AI governance, data quality, and interoperability top industry agenda in mid-2026

The article discusses the challenges faced by healthcare IT leaders in terms of AI governance, data quality, and interoperability by mid-2026. A significant effort is being made to address data readiness challenges and to enhance health data exchange through a $1.3 million federal initiative. These topics are at the forefront of the industry's agenda to improve healthcare infrastructure and outcomes.

  • 01AI governance gaps are challenging healthcare IT leaders.
  • 02Data readiness is a critical concern in healthcare.
  • 03Federal funding is supporting health data exchange initiatives.

Jul 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub